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Objective: Human β-defensin (HBD) and the complement system are two important
innate immune mechanisms active against a broad range of burn and wound pathogens.
However, excessive or uncontrolled complement activation, following thermal injury,
contributestotissuedamage.Previousstudiesfromourlaboratorysuggestedadecreased
expression of HBD-2 in burn wounds and its absence in burn blister fluid. Prior studies
have demonstrated that human neutrophil peptide can bind to the C1q component of
the complement system and prevent complement activation. The objective of this study
was to determine whether HBD-1 and HBD-2 can also bind to the C1q component and
modulate complement activity. Methods: The binding efficiency of HBD-1 and HBD-2
to the C1q component was determined by utilizing dot blot hybridization. The effect
of HBD-2 on the activation of the complement system by the classical and alternative
pathways was determined by CH50 and AP50 assays. In addition, the ability of HBD-
1 and HBD-2 to inhibit C1q activity was predicted by a comparison with known C1q
inhibitor peptide 2J in a DNAStar computer modeling study. Results: C1q binding to
HBD-2 was strong, whereas C1q binding to HBD-1 was weak. HBD-2 inhibits the
classical pathway significantly without affecting the alternative pathway. In addition, a
computer modeling study also revealed structural homology of HBD-2 with known C1q
inhibitory sequences of HBD-2. Conclusion: HBD-2 inhibits the classical pathway. The
replacementofmissingdefensin,anaturalinhibitorofthecomplementsystem,mayhave
a dual protective role not only as an antimicrobial agent but also in providing protection
against uncontrolled activation of the complement system.
Burn wound sepsis is a common and often fatal sequel in patients suffering from
major thermal injury.1 Severely burned skin ceases to perform its natural protective role
and surrenders itself as a nidus and portal for bacterial invasion. Multiple organ failure
syndrome remains a problem in patients with extensive deep burns. The activation of a
proinflammatory cascade after burn injury appears to be important in the development of
subsequentimmunedysfunction,susceptibilitytosepsis,andmultipleorganfailure.1–5Most
therapeutic strategies directed specifically toward neutralizing inflammatory mediators or
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cytokines to control sepsis have failed in clinical trials, and the treatment of established
organ failure is usually not successful.2 Despite various current topical treatment regimens
designed to eradicate the bacterial load within the burn wound, sepsis remains the leading
cause of death in burn units around the world.1−3
Thermalinjuryisassociatedwithimmunesuppression,whichincludesbothinnateand
adaptive immune systems.4−6 Innate immunity is largely conferred by the complement sys-
tem,leukocytes,andrecentlycharacterizedantimicrobialpeptides,whichincludedefensins
and cathelicidins.7−9 A problem arises if the innate immune mechanisms are overactive, a
feature observed in burns.8
Defensins, a large family of broad-spectrum antimicrobial peptides, are expressed at
the cell surface and function as a biochemical barrier against microbial infection by in-
hibiting colonization of a wide range of pathogenic microorganisms, including burn wound
pathogens.7,9,10 In humans, defensins are classified into 2 families designated α and β
based on distinctive, although similar, tri-disulfide linkages. Six α-defensins—human neu-
trophil peptides (HNP), HNP-1 to HNP-4, human defensin 5 (HD-5), and HD-6—and 4
β-defensins—human β-defensins, HBD-1 to HBD-4—have been identified in humans.
The defensins are also implicated in potentiating innate and adaptive immunity; have been
shown to induce histamine release by mast cells,10 chemoattract neutrophils, macrophages,
monocytes, T cells and B cells as well as dendritic cells; and alter antibody production.11,12
The activation of the complement system is an important first line of defense against
microbial infection.8,13,14 Its principal role is the recruitment of inflammatory cells and the
killing or opsonization of microorganisms. The complement system consists of more than
30 serum and cellular proteins. Activation of the system occurs by 3 biochemical pathways,
the classical, the alternative, and the mannin-binding lectin (MBL) (Fig 1). The classical
pathway is initiated when antibodies bind to antigens on the surface of the microbe. The
subsequent binding of this antibody complex to C1, the first component of the complement
system, splits C1 into subcomponents C1q, C1r, and C1s. Released C1r and C1s are pro-
teases that activate the cascade. The MBL pathway is triggered by the binding of MBL in
serum to polysaccharides on the surface of the microbe and activation of MBL-associated
serine proteases. The alternative pathway is initiated by deposition of the spontaneously
generated C3b component on bacterial surfaces. All 3 steps terminate in a final common
pathway, ultimately leading to the formation of the membrane attack complex that lyse mi-
croorganisms.TheC3bfragmentdepositedonthemicrobialsurfacecanserveasanopsonin
to promote phagocytosis.9 Activation of the complement system is well controlled inter-
nally. Its overactivation is mainly prevented by a number of naturally occurring inhibitors,
such as the inhibitor of C1, C1-Inh, which inhibits the serine proteases C1r and C1s of the
classical pathway.
It has been shown that human neutrophil defensins predominantly bind to the first
component C1 and C1-Inh,15 suggesting that complex formation between defensins and C1
inhibit activation of the complement system and may also inhibit the cytolytic activity of
defensins.15 InourpreviousstudieswehaveshownthattheexpressionofHBD-2isreduced
in burned skin and absent in burn blister fluid.16−19 The absence of HBD-2 may lead to
decreased local antibacterial action and lack of inhibition of an overactive complement
system, which might predispose the person to the development of sepsis and multi organ
failure. The interaction between HBD and the complement system has not been previously
reported. We have, therefore, studied the binding of HBD-1 and HBD-2 to C1q, to assess
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whether this interaction will affect the classical and alternative complement pathways. We
have also compared the structural homology between HBD-2 and the known C1q-binding
sequence of complement inhibitors using computer modeling.
Figure 1. The complement system consists of about 30 proteins that can be activated by 3 differ-
ent cascades. The classical pathway is initiated when antigen-antibody complexes bind to the C1q
component of C1, resulting in release of C1s and C1r, which act as protease to cleave C2 and C4.
The mannin-binding lectin (MBL) pathway is triggered by activation of MBL-associated serine pro-
teinases (MASP-1 and MASP-2) following the binding of polysaccharides on microbes to MBL.
MASP-1 and MASP-2 convert C2 and C4. The alternative pathway is triggered by the deposition
of spontaneously generated C3b on microbes, leading to the generation of alterative C3 convertase.
The common final step is the activation of C5 by C5 convertases, which leads to the formation of
the membrane attack complex that finally inserts into target cell membranes and causes cell lysis.
The peptides C3a, C4a, and C5a mediate several reactions in the inflammatory response that could
cause tissue injury when complement activation becomes uncontrolled.
MATERIAL AND METHODS
Dot blot hybridization
Full-length HBD-1 and HBD-2 peptides were synthesized at the Louisiana State University
Medical Center, Core Laboratory. Peptides (20 mg/mL) were dissolved in 88% formic acid.
Thelevelsofbindingoffull-lengthHBD-1andHBD-2peptidestoC1qweredeterminedby
dotblothybridization.Fourmicrolitresofpeptide(HBD-1,HBD-2,orbovineserumalbumin
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[BSA]) samples diluted with tris-buffered saline (TBS) to achieve required concentrations
were blotted onto Trans blot transfer membrane (0.2 μm, Bio-Rad, Hercules, Calif). All
incubations were at room temperature unless otherwise indicated. The membranes were
rinsed in 20 mL of tris-buffered saline with Teween-20 (TBST), blocked with 20 mL of
5% nonfat dry milk in TBST for 1 hour, and rinsed briefly with TBST. All subsequent
incubations contain TBST plus 1% nonfat dry milk. The membrane was incubated with
human C1q (Quidel, San Diego, Calif; 10 μg/mL) for 3 hours. The membrane was then
washed and incubated with rabbit antihuman C1q antibody (DAKO, Carpinteria, Calif)
diluted1:1000in1%nonfatdrymilkinTBST.Afterwashing,themembranewasincubated
with goat antirabbit IgG, HRP (Sigma-Aldrich, St. Louis, Mo) at a dilution of 1:500 for
1 hour. The membrane was washed again and the signal was detected using the ECL system
(Amersham Bioscience, Piscataway, NJ). The membrane was exposed to CH-screen for
45 minutes, and the image was quantified using the Phosphor Imager (GS-250, Bio-Rad,
Hercules, Calif).
Complement activity
The CH50 and AP50 hemolytic assays were adapted from the published procedure by Roos
et al20 to determine activation of the complement system by the classical and alternative
pathway, respectively, and to study the inhibitory properties of test peptides on complement
activation. The CH50 hemolytic assay and AP50 hemolytic assay kits were purchased
from Advanced Research Technologies (San Diego, Calif) and used as per manufacturer’s
instruction.
For hemolytic assays of classical pathway complement activation, sheep red blood
cells were sensitized using rabbit antisheep red blood cell anti-bodycoated erythrocytes.
For analysis of classical pathway activity, a hemolytic activity of the classical component
pathway (CH50) test was performed, in which 1 × 107 erythrocytes were incubated in
the presence of normal human serum diluted in dextrose gelatin Veronal buffer (0.5 ×
VBS, 0.05% gelatin, 167 mM glucose, 0.15 mM CaCl2, 0.5 mM MgCl2; final volume
200 μL). Similarly, a C1q-dependent hemolysis test was performed using C1q-depleted
humanserum,diluted1/75,andalimitingamountofpurifiedC1q.Foranalysisofalternative
pathway activity, a hemolytic activity of the alternative complement pathway (AP50) test
was performed, in which 1 × 107 rabbit erythrocytes were incubated with human serum
diluted in dextrose gelatin Veronal buffer containing 10 mM MgEGTA. In all these assays,
HBD-2wastestedbypremixingappropriateconcentrationsofHBD-2withthecomplement
source before addition of the mixture to the erythrocytes, followed by 60-minute incubation
at 37◦C. After addition of 1.5 mL of phosphate buffered saline (PBS) and centrifugation,
hemolysis was assessed by measuring the optical density (OD) at 414 nm. The lytic activity
of condition x was expressed in Z values: Z =− ln{1 − [OD414 (x)− OD414 (0%)/(OD414
(100%) − OD414 (0%))]}, in which OD414 (0%) represents incubation of erythrocytes with
buffer only. OD414 (100%) was assessed after addition of H2O. The amount of complement
added was chosen such that the Z value in the absence of inhibitors was between 0.5 and
1.5. In general, serum was diluted 1/200 for a CH50 assay and 1/10 for an AP50 assay.
The results are expressed as relative hemolytic activity and calculated as the ratio of the
Z value in the presence of the inhibitor and the Z value in the absence of the inhibitor.
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In some experiments, the percentage lysis was determined relative to a reagent blank and
100% lysis, expressed as units/mL (Z) and converted to percentage inhibition.
Comparison of sequence homology
Comparison of alfa helix display of consensus sequence between peptide 2J21 and HBD-2
andtheiroverlapwerecarriedoutusingLaserGenesoftware(DNAStar,www.dnastar.com).
Statistical analysis
Alldataareexpressedasthemean±SEMofatleastseparateexperimentsunlessotherwise
stated in the figure legend. Statistical analysis was performed using 2-tailed Student t
test for unpaired samples with unequal variances. Differences were considered statistically
significant at P <. 05.
RESULTS
HBD-2 binds strongly to C1q whereas HBD-1 binds poorly
Our data (Fig 2) show that HBD-2 binds strongly to C1q in a dose-dependent manner,
whereas HBD-1 binds poorly. The quantified volume counts of dots in the phosphor imager
are demonstrated in the bar chart in Figure 2. HBD-2 bound significant amounts of C1q
even at a concentration of 0.25 μg, whereas HBD-1 did not show any detectable binding at
this concentration. The BSA, used as a control protein to detect unspecific binding, did not
show any C1q binding, indicating that the binding of C1q to HBD-2 is specific.
HBD-2 inhibits the classical complement pathway without affecting the
alternative pathway
The effect of HBD-2 on classical and alternative pathways of complement activation was
studied using hemolytic assays. Our data (Fig 3) show that binding of HBD-2 is accompa-
nied by inhibition of the classical pathway of complement activation without affecting the
alternative pathway.
HBD-2 shows homology with known inhibitor of C1q activation
Roos and coworkers20 screened 42 peptides for their ability to inhibit the function of
C1q. These peptides were selected from phage-displayed peptide libraries on the basis
of their C1q-binding ability, and it was found that peptide 2J was the most active C1q in-
hibitor. Peptide 2J [CEGPFGPRHDLTFCW] inhibited the hemolytic activity of C1q from
human, chimpanzee, rhesus monkey, rat, and mouse with a similar dose-response relation-
ship.Comparisonofthehomologousregion(“Consensus”)[GXFGXXXDXXXC]between
HBD-2[LPGVFGGIGDPVTCL]andpeptide2J[CEGPFGPRHDLTFCW]mayexplainthe
observed inhibition of C1q by both HBD-2 and peptide 2J. This GXFGXXXDXXXC con-
sensus is primarily on one side of an alpha helix (Fig 4) and is in the region of HBD-2 that
contains the protease cleavage site where the signal peptide is removed by tissue metallo-
protease (“matrilysin”) to produce active HBD-2. Thus, both peptide 2J and HBD-2 may
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Figure 2. The dot blot hybridizations were carried out
as described in the “Material and Methods” section.
The quantified Phosphor Imager counts were plotted
against different peptide concentrations. *Significance
(P <. 05).
be able to bind to the active site of C1q (globular head) and act as (protease) inhibitors to
produce the observed inhibition of C1q activation.
DISCUSSION
In this study, we have demonstrated that HBD-2 can bind to the C1q component of the
complement system and inhibit activation of the classical pathway. A study from Van Den
Berg and coworkers has shown that the binding of HNP-1 to C1q inhibited the activation
of the classical pathway as evidenced by CH50 assay.22
Complementactivationisaveryimportantinnateimmunedefensemechanismagainst
invading microbes. Some activation is necessary for an efficient clearance of bacteria or
their products, while excessive or uncontrolled activation can lead to inflammation and
tissue injury, as seen with thermal injury.23 The C3a, C4a, and C5a peptides released during
complement activation leads to increased inflammatory responses.24−26 Complement com-
ponent C5a and membrane attack complex (MAC) have proinflamatory effects such as
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Figure 3. The effect of HBD-2 on hemolytic activ-
ity (CH50 and AP50) was determined as described
inthe“MaterialandMethods”section.Thepercent-
age of lysis was determined relative to a reagent
blankand100%lysis,expressedasunits/mL(Z)and
converted to percentage inhibition. *Significance
(P <. 05).
accumulation and stimulation of neutrophils and may increase the permeability of endothe-
lial cells, mediated in part by histamine, and promote coagulation by inducing expression
of tissue factor. C5a is able to induce or enhance the production of cytokines IL-1, TNF,
and IL-6 by monocytes. Inhibition of complement activation is considered a major target
for drug design and treatment of inflammation-related disorders.20,21,27−30 In a porcine
model for thermal injury, C1-Inh was shown to have beneficial effects in the acute stage
of thermal injury by reducing organ alterations, improving microcirculation, and largely
preventing bacterial translocation in the gastrointestinal tract.8 Favorable effects of C1-Inh
administration to patients with burns have been reported.
The therapeutic application of complement inhibitors, to prevent undesired effects of
complement activation, is currently under development. The main culprit for tissue damage
is the classical pathway and a number of inhibitors of this pathway have a proven efficacy
in a number of diseases including burns and sepsis. This includes the use of C1-Inh and
IgG.8,13 The soluble form of CR1 receptor and Compstatin, a synthetic peptide inhibitor of
C3, have also been shown to prevent complement-related damage.29,30
C1q is considered one of the main targets identified for complement inhibition. Re-
cently,Lauvrakandcoworkersreportedthesequencesof42peptidesthatwereselectedfrom
phage display libraries on the basis of their ability to bind to human C1q.21 These peptides
were studied in detail for their anticomplement activity. The peptide 2J (15 amino acids)
showed optimum C1q-binding properties. This peptide inhibits C1q from human, primate,
and rodent origins and was proposed as a promising candidate for further development
as a therapeutic C1q inhibitor.20 Using computer modeling we found that HBD-2 shares
homology with peptide 2J. We therefore hypothesize that HBD-2 qualifies as a complement
inhibitor.
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Figure 4. Alfa helix display of consensus sequence between peptide 2J and HBD-2 and
their overlap using Laser Gene software.
In summary, we report binding of HBD-2 to the C1q component of the complement
system and inhibition of its classical pathway. Computer modeling has revealed significant
homology between HBD-2 and known complement inhibitor peptide 2J, predicting inter-
action between HBD-2 and C1q. To our knowledge, this is the first report of the interaction
of human beta defensins and the complement system, findings that require a detailed study
to explore the utility of such interaction in thermal injury and sepsis.
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